PB-004

N/A

Report date: 2024/02/26 20:04:27

Base Information

Drug NamePB-004

Drug Alias NamePB-004PB004PBA-0405PB004 PureBIKE

ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionNatural killer cells stimulantsAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPoland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPure Biologics SA

China Registration ClassN/A

Develop Information

Active CompaniesPure Biologics SA

Inactive CompaniesN/A

Active IndicationsSolid tumoursTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A